Tucatinib
Showing 51 - 59 of 59
HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)
Not yet recruiting
- HER2
- Colorectal Cancer
- Disitamab Vedotin Combined With Fruquintinib
- (no location specified)
Dec 21, 2022
Healthy Trial in Madison (tucatinib)
Completed
- Healthy
- tucatinib
-
Madison, WisconsinCovance Clinical Research Unit
Nov 28, 2018
HER2-low in Metastatic Breast Cancer Patients
Not yet recruiting
- HER2-negative
- (no location specified)
Nov 9, 2023
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult Trial (Patritumab deruxtecan)
Not yet recruiting
- Metastatic Breast Cancer
- +2 more
- Patritumab deruxtecan
- (no location specified)
May 9, 2023
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in United States (Crizotinib, Palbociclib, Sunitinib)
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Crizotinib
- +17 more
-
Birmingham, Alabama
- +125 more
Nov 21, 2022
Breast Cancer Trial in Worldwide (Trastuzumab Deruxtecan)
Recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
-
San Diego, California
- +90 more
Jul 19, 2022
Colorectal Tumors Trial in China (Disitamab vedotin, Tislelizumab)
Recruiting
- Colorectal Neoplasms
- Disitamab vedotin
- Tislelizumab
-
Changzhou, Jiangsu, China
- +5 more
Aug 7, 2022
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer Trial in Worldwide (Giredestrant, Abemaciclib,
Recruiting
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
- Giredestrant
- +9 more
-
Duarte, California
- +27 more
Jan 31, 2023
Breast Tumors, Chemotherapeutic Toxicity Trial in Quebec City (Application)
Recruiting
- Breast Neoplasms
- Chemotherapeutic Toxicity
- Application
-
Quebec City, Quebec, CanadaSt-Sacrement Hospital
Feb 24, 2023